Market research
ALDEI.PA Deinove SA
PA EUR Energy
Latest close
Latest stored close unavailable
Test a moving-average rule with historical data.
Market facts
- Market cap
- 1M
- P/E ratio
- Not available
- Analyst target
- 0.6
- Dividend yield
- 0.0%
- Beta
- 0.79
Profile
Instrument facts
- Exchange
- PA
- Currency
- EUR
- Sector
- Energy
- Industry
- Renewable Energy
- ISIN
- FR0010879056
- Market cap
- 1M
- P/E ratio
- Not available
- Analyst target
- 0.6
- Dividend yield
- 0.0%
- Beta
- 0.79
About
About Deinove SA
DEINOVE SA, a biotechnology company, discovers, develops, and produces compounds from microbials for the health, nutrition, and cosmetics industries worldwide. The company's pipeline includes DNV3837, an antibiotic, which is in the Phase II clinical trial for the treatment of Clostridioides difficile infections. It also offers Dual-Acting Small Molecule Antibiotics, a class of dual activity antibiotics that develops a new class of 2-in-1 molecules whose structure results from the combination of two active antibiotic moieties. The company was founded in 2006 and is based in Grabels, France.
Research context
Deinove SA appears in PyInvesting’s Paris Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Energy
- Industry
- Renewable Energy
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the ALDEI.PA discussion.
5 years, 6 months ago
Deinove SA is currently in a long term downtrend where the price is trading 22.7% below its 200 day moving average.
From a valuation standpoint, the stock is 84.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 42.7.
Finally, its free cash flow grew by 44.4% to $-665K since the same quarter in the previous year.
Based on the above factors, Deinove SA gets an overall score of 2/5.